Keytruda and TVec combination results presentation

Amgen are presenting data on their combination study with Keytruda this weekend.

The Phase 1b data on IMLYGIC in combination with an investigational use of Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with unresectable metastatic melanoma (NCT02263508) has been accepted as a late-breaking abstract. The oral presentation is Saturday, Nov. 21, in Plenary Session 11 (Late Breaking Clinical Updates) between 1:30 to 3:40 p.m. PT in the San Francisco Marriott Marquis Salon 9-15:

If the preliminary results are promising this should be great news for Cavatak.  It would be logical to think the results from our Cavatak Keytruda trial will be as good or better.